Invitae, San Francisco, California, USA.
Perkin Elmer, Duluth, Georgia, USA.
Hum Mutat. 2022 Aug;43(8):1097-1113. doi: 10.1002/humu.24302. Epub 2021 Dec 2.
The genes MECP2, CDKL5, FOXG1, UBE3A, SLC9A6, and TCF4 present unique challenges for current ACMG/AMP variant interpretation guidelines. To address those challenges, the Rett and Angelman-like Disorders Variant Curation Expert Panel (Rett/AS VCEP) drafted gene-specific modifications. A pilot study was conducted to test the clarity and accuracy of using the customized variant interpretation criteria. Multiple curators obtained the same interpretation for 78 out of the 87 variants (~90%), indicating appropriate usage of the modified guidelines the majority of times by all the curators. The classification of 13 variants changed using these criteria specifications compared to when the variants were originally curated and as present in ClinVar. Many of these changes were due to internal data shared from laboratory members however some changes were because of changes in strength of criteria. There were no two-step classification changes and only 1 clinically relevant change (Likely pathogenic to VUS). The Rett/AS VCEP hopes that these gene-specific variant curation rules and the assertions provided help clinicians, clinical laboratories, and others interpret variants in these genes but also other fully penetrant, early-onset genes associated with rare disorders.
MECP2、CDKL5、FOXG1、UBE3A、SLC9A6 和 TCF4 等基因给当前 ACMG/AMP 变异解读指南带来了独特的挑战。为了解决这些挑战,Rett 和 Angelman 样疾病变异解读专家小组(Rett/AS VCEP)起草了特定基因的修改建议。进行了一项试点研究,以测试使用定制变异解读标准的清晰度和准确性。多名解读员对 87 个变体中的 78 个变体(~90%)得出了相同的解读,这表明大多数情况下所有解读员都正确地使用了修改后的指南。与最初进行的变异解读和 ClinVar 中的变体相比,使用这些标准规范对 13 个变体进行了分类更改。这些更改中有许多是由于实验室成员共享的内部数据所致,但有些更改是由于标准强度的变化所致。没有两步分类更改,只有 1 个临床相关的更改(可能致病性为 VUS)。Rett/AS VCEP 希望这些特定基因变异解读规则和断言能够帮助临床医生、临床实验室和其他人员解读这些基因以及其他与罕见疾病相关的完全外显、早发性基因中的变异。